GlaxoSmithKline Partners with CureVac to Develop mRNA-based Vaccines

By Pratika Pahwa & Michelle Liu

Pharma Deals Review: Vol 2020 Issue 7 (Table of Contents)

Published: 29 Jul-2020

DOI: 10.3833/pdr.v2020.i7.2550     ISSN: 1756-7874

Section: Research & Development



Expanding its footprint in vaccine business, GlaxoSmithKline (GSK) has agreed to partner with CureVac to develop and commercialise up to five mRNA-based vaccines and monoclonal antibodies targeting infectious diseases...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details